351 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (182)
- Autoimmune Disorders (3)
- Blood Disorders (8)
- Cancer
(111)
- Bladder Cancer (1)
- (-) Brain Cancer (2)
- (-) Breast Cancer (2)
- Gastrointestinal (3)
- Gynecologic Cancer (3)
- Head and Neck Cancer (2)
- Kidney Cancer (3)
- Leukemia (9)
- Liver Cancer (1)
- Lung Cancer (14)
- Lymphoma (8)
- Multiple Myeloma (6)
- Pancreatic Cancer (1)
- Prostate Cancer (9)
- Sarcoma (4)
- Skin Cancer (5)
- Solid Tumors (7)
- Diabetes (1)
- Healthy Volunteers (3)
- Heart Disease (2)
- Infectious Disease (3)
- Neurological Disorders (16)
- Nutrition (1)
- Obstetrics & Gynecology (1)
- Pediatrics (15)
- Psychiatric Disorders (1)
- Transplant (16)
- Urology (1)
Displaying 1 - 4 of 4
Condition: Cancer / Brain Cancer
Investigator: Fabio Iwamoto, MD
Status: Currently Recruiting
The purpose of this study is to learn the effects of the investigational new drug, tirabrutinib, when given for the treatment of PCNSL. Investigational new drug means a drug that has not been approved as a marketed product (that is, available to be prescribed or sold) by the United States (US) Food and Drug Administration (FDA). Tirabrutinib acts by…
Condition: Cancer / Breast Cancer
Investigator: Julia McGuinness, MD
Status: Currently Recruiting
The purpose of this research is to test how well an investigational study drug (medication), GLSI-100, can prevent your cancer from coming back. The research study will also collect information about the safety of the medication. The research will also study how the medication works and who responds the best to the medication. GLSI-100 is a combination of a…
Condition: Cancer / Brain Cancer
Investigator: Andrew Lassman, MD
Status: Closed
The purpose of this study is to evaluate and determine the efficacy of pemigatinib in participants with recurrent glioblastoma or other CNS tumors with changes in the FGFR1, FGFR2 or FGFR3 genes. Pemigatinib (also referred as INCB054828) is an investigational drug that is being studied by Incyte Corporation (Sponsor) for use in the treatment of previously…
Condition: Cancer / Breast Cancer
Investigator: Dawn Hershman, MD
Status: Closed
This randomized clinical trial studies prophylactic colony stimulating factor management in patients with breast, colorectal or non-small cell lung cancer receiving chemotherapy and with risk of developing febrile neutropenia. Patients receiving chemotherapy may develop febrile neutropenia. Febrile neutropenia is a condition…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE